Compare Sunrun Inc (RUN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs Sana Biotechnology Inc — how do they compare? Sunrun Inc trades at $11.46 (market cap $2.73B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Sunrun Inc is far larger — about 3.1× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| RUN | SANA | |
|---|---|---|
Market Cap | $2.73B | $873.84M |
Sector | Technology | Health |
52-Week High | $21.41 | $5.92 |
52-Week Low | $9.07 | $2.68 |
Enterprise Value | $16.92B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook. The stock shows strong profitability with a 17.88% net income margin and trades at a low P/E of 5.56. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, boosting growth prospects. Earnings have consistently beaten estimates, with Q1 2026 EPS of $0.62 versus -$0.05 expected.
The outlook is mixed: analyst consensus is bullish with a $16.27 price target, but cash flow concerns and high debt-to-asset ratio of 70.76% pose risks. The partnership with Tesla offers significant upside in the AI-driven energy demand sector, yet execution and financing challenges remain key hurdles for sustained growth.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
